Chronic lymphocytic leukemia (CLL) is a slow-growing type of blood cancer and the most common form of leukemia in adults. CLL results in large numbers of abnormal B lymphocytes in the bone marrow and prevents the production of healthy blood cells. It is more commonly diagnosed in older people: almost 80% of cases are in people over 60 years old. Changes in chromosomes or genes in some patients affect how the disease develops and what treatment is prescribed. CLL cannot be completely cured but many people will have a normal lifespan and a good quality of life.
Chronic lymphocytic leukemia (CLL) is the most diagnosed leukemia in the Western world, accounting for approximately 25% of all new leukemia diagnoses. In recent years, remarkable progress has been made in our understanding of both the pathophysiology and genetics of CLL. While the disease generally affects older adults and initially follows an indolent course, cytogenetic and molecular profiling have helped to predict clinical outcomes. Greater prognostication, alongside the development of an increasing armamentarium of novel targeted therapies, has enabled us to provide more personalized management options for patients. Table of Contents • Epidemiology and etiology • Molecular biology and genetics • Diagnosis, staging and prognosis • Management • Research directions
Chronic lymphocytic leukemia (CLL) is the most diagnosed leukemia in the Western world, accounting for approximately 25% of all new leukemia diagnoses. In recent years, remarkable progress has been made in our understanding of both the pathophysiology and genetics of CLL. While the disease generally affects older adults and initially follows an indolent course, cytogenetic and molecular profiling have helped to predict clinical outcomes. Greater prognostication, alongside the development of an increasing armamentarium of novel targeted therapies, has enabled us to provide more personalized management options for patients. 'Fast Facts: Chronic Lymphocytic Leukemia' covers the epidemiology, etiology, diagnosis and staging of the disease, and the molecular and genetic aspects that underpin treatment and prognosis. It provides a concise overview of treatment options, in both the front-line and relapsed/refractory settings, with particular focus on the novel targeted agents that have overcome many adverse prognostic factors, improving overall survival. Table of Contents: • Epidemiology and etiology • Molecular biology and genetics • Diagnosis, staging and prognosis • Management • Research directions
Leukemia is a hematologic malignancy arising from hematopoietic stem cells (HSCs) in the bone marrow. Starting with a detailed description of hematopoiesis and what goes wrong in leukemia, this concise guide covers all aspects of the four most common subtypes of the disease. Although the incidence and prevalence of leukemia are rising worldwide, survival rates are also increasing. However, both the effects of the disease and the adverse effects of treatment remain complex challenges. Yet, as our understanding of the molecular landscape increases, therapeutic options are becoming more personalized. This revised and updated second edition of 'Fast Facts: Leukemia' addresses the causes and risk factors for each subtype of leukemia, the initial and confirmatory diagnostic tests, and the latest treatment options. Designed as a comprehensive primer for physician assistants, nurse practitioners, primary care providers, oncology nurses, hematology/ oncology trainees and pharmacists, this resource will help the non-specialist and those in training to identify leukemia early and provide a thorough understanding of the pathology and genetic basis of the disease, treatment options, and effective approaches to emergency and supportive care. Table of Contents: • Understanding blood and its components • What is leukemia? • Epidemiology, etiology and risk factors • Diagnosis • Staging and general management • Supportive care • Emergencies in leukemia
The tyrosine kinase inhibitor (TKI) imatinib was the first treatment to specifically target cancer cells, rather than the relatively indiscriminate effects of conventional chemotherapy on any rapidly dividing cells. This concept of targeted treatment in cancer is one of the important advances in modern medicine in the last 30 years. Indeed, treatment with TKIs has transformed chronic myeloid leukemia (CML) from a cancer with a poor prognosis to one in which many patients can expect a normal lifespan. Success with the TKIs has prompted the question of whether it is desirable – or feasible – for patients to remain on treatment for long periods. While the TKIs are targeted, they are associated with considerable toxicity, and long-term treatment has important economic implications for health services and patients. Thus, the concept of treatment-free remission (TFR) has emerged for patients in deep clinical remission. Clinical research over the last decade has focused on whether treatment can be stopped, how to best monitor patients while off treatment, and how to intervene before a clinical relapse. As this research progresses, the tantalizing prospect of a cure for some patients seems increasingly feasible. This new Fast Facts title outlines this trail-blazing approach to the long-term management of patients living with CML in remission. It explains the concepts of molecular and hematologic relapse, the highly sensitive technologies that allow disease monitoring, and how TFR is best managed in practice. It is a concise educational resource, ideal for any healthcare professional involved in the treatment of patients with CML who wants to understand TFR, particularly clinical nurse specialists and pharmacists who increasingly help clinicians to run CML clinics. Table of Contents: • The concept of treatment-free remission • Measurement of disease burden • Clinical practice • Future directions
Aunque la incidencia y prevalencia de leucemia está aumentando a nivel mundial, los avances en el diagnóstico y el tratamiento indican que las tasas de supervivencia también están aumentando. Comenzando con una descripción detallada de la hematopoyesis y lo que está mal en caso de la leucemia, esta guía concisa abarca todos los aspectos de los cuatro subtipos más frecuentes de la enfermedad: leucemia mieloide aguda (AML), leucemia linfoblástica aguda (ALL), leucemia mieloide crónica (CML) y leucemia linfocítica crónica (CLL). Este libro considera las causas y factores de riesgo para cada subtipo de leucemia, las pruebas diagnósticas iniciales y confirmatorias (incluyendo métodos de citogenética y genética molecular) y las opciones de tratamiento más recientes. Tanto los efectos de la enfermedad como los efectos adversos del tratamiento siguen representando un desafío complejo y se considera el abordaje multidisciplinario necesario para una atención de apoyo efectiva. Por último, se examinan las complicaciones urgentes que requieren atención de emergencia. Diseñado como una guía integral para enfermeras especializadas, médicos de atención primaria y residentes de hematología/oncología, este recurso ayudará a quienes no son especialistas a identificar la leucemia en etapas tempranas y proporciona una comprensión detallada de la patología y la base genética de la enfermedad, las opciones de tratamiento y los abordajes efectivos a la atención de urgencia y cuidados de apoyo.
For nearly 25 years, Ferri's concise, pocket-sized resource has served as the go-to reference for practical, clinical information among students, residents, and other medical professionals. Formerly known as Practical Guide to the Care of the Medical Patient, this volume continues to provide a fast, effective, and efficient way to identify the important clinical, laboratory, and diagnostic imaging information you need to get through your internal medicine clerkship or residency. - Consult this title on your favorite device, conduct rapid searches, and adjust font sizes for optimal readability. - Benefit from the expert guidance of Dr. Fred Ferri, a leading teacher, clinician, and author. - Confidently manage patients with the latest clinical information, drug therapies, and lab tests. - Apply the latest knowledge and techniques with this updated and streamlined title, which still stays true to the Ferri name. - Quickly find important information with content organized into three major sections: Section I, titled "Surviving the Wards," contains information on charting, laboratory evaluation and formulary; Section II provides the differential diagnosis of common signs and symptoms likely to be encountered in the acute care setting; Section III has been completely revised and subdivided into 11 specialty specific diseases and disorders. - Carry just the sections you need, add personalized materials, and keep everything together and safe with an improved ring binder and design. - Access the full text and procedural videos online at Expert Consult.
Lymphoma affects all ages. Advances in diagnostic cellular and molecular techniques coupled with new treatment options are improving patient outcomes. This third edition of our bestselling 'Fast Facts: Lymphoma' distills the most important aspects of diagnosis and management into an up-to-date and highly accessible well-illustrated overview that includes: • a clear outline of the nature of lymphoma • the essentials of clinical presentation, biopsy and histology • a synopsis of current laboratory diagnostics, including immunophenotyping, cytogenetics and microarray technology, and updated to include the latest molecular genetic techniques • key aspects of staging and initial therapy • clearly illustrated overviews of the pathology, presentation, treatment and prognosis of each lymphoma subtype • new treatment options, including targeted biological therapies and chimeric antigen receptor T cells (CAR T cells) • a practical overview of supportive care for the complications of lymphoma. Written by three lymphoma experts from the UK and USA, 'Fast Facts: Lymphoma' gives an interesting international perspective to this challenging disease. Its clarity and colorful format make it a valuable resource for senior health professionals seeking an accessible update in this area of hemato-oncology, trainee doctors and specialist nurses who are new to it, and individuals affected by lymphoma and seeking more information. Contents: • Epidemiology • Cellular and molecular aspects • Presentation, biopsy and diagnostic laboratory techniques • Staging and general management principles • Aggressive B-cell lymphomas • Indolent B-cell lymphomas • T-cell and natural-killer cell lymphomas • Immunocompromised and HIV-positive patients • Hodgkin lymphoma • Treatment modalities • Supportive care
Skin cancer is both preventable and treatable, yet it is becoming alarmingly common. The key to successful treatment (other than education and prevention) is early recognition and swift referral. 'Fast Facts: Skin Cancer' has been written by three international experts to equip healthcare professionals with the necessary skills to save lives. Highlights include: • Expert presentation of the basic facts on epidemiology, causation, presentation and management • Over 100 color illustrations to assist with the identification of at-risk individuals and early lesions • Pull-out tables of cancer staging for cutaneous squamous cell carcinoma and melanoma • Advice to give patients on self-examination • A thorough overview of all treatment options: topical therapies, cryotherapy, curettage and electrosurgery, photodynamic therapy and lasers, radiotherapy, surgical excision and Mohs micrographic surgery • Discussion of preventive measures This fully updated second edition is a practical evidence-based resource, written from an international perspective to reflect national and international guidelines. It will assist clinical practice, education, training, audit and research, and is essential reading for generalists and specialists alike. Contents: • Epidemiology • Pathogenesis • Clinical features and diagnosis • Management • Prognosis • Prevention; Future trends
Hodgkin lymphoma and the many different subtypes of non-Hodgkin lymphoma (NHL) have different responses to treatment, so accurate diagnosis and a rational approach to management are essential. 'Fast Facts: Lymphoma' distills the most important aspects of the diagnosis and management of these complex disorders into a highly accessible well-illustrated summary of the key facts. This fully updated second edition provides: • a clear outline of the nature of lymphoma • the essentials of clinical presentation, biopsy and basic histology • the latest laboratory diagnostics, including immunophenotyping, cytogenetics and microarray technology • key aspects of staging and initial therapy • superbly illustrated overviews of the pathology, presentation, treatment and prognosis of each lymphoma subtype • new treatment options, including targeted biological therapies • a practical overview of supportive care for the complications of lymphoma Written by three experts in the field from the UK and USA, 'Fast Facts: Lymphoma' applies an international perspective to this challenging disease in a unique format within the context of clinical practice. It is a valuable resource for trainee doctors and specialist nurses working in the field of hemato-oncology. It will also be of interest to the inquiring patient or carer who wishes to know more about lymphoma. Contents: • Epidemiology • Cellular and molecular aspects • Presentation, biopsy and diagnostic laboratory techniques • Staging and general management principles • Aggressive B-cell lymphomas • Indolent B-cell lymphomas • T-cell and natural-killer cell lymphomas • Immunocompromised and HIV-positive patients • Hodgkin lymphoma • Treatment modalities • Supportive care
